Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section
Photo of Eric R. Wenzler

Eric R. Wenzler

Assistant Professor, Pharmacy Practice

Contact Information

833 S. Wood Street (886)
Room 120
Chicago, Illinois 60612

Phone: (312) 996-7440

Fax: (312) 996-0379

Lab Phone: (312) 413-2986

Education

  • Infectious Diseases Pharmacotherapy Fellowship, University of Illinois at Chicago, Chicago, IL, 2017
  • PGY-2 Infectious Diseases Pharmacy Residency, ASHP Accredited, Ohio State University Wexner Medical Center, Columbus, OH, 2014
  • PGY-1 Pharmacy Practice Residency, ASHP Accredited, Ohio State University Wexner Medical Center, Columbus, OH, 2013
  • PharmD, Cum laude, Ohio Northern University Raabe College of Pharmacy, Ada, OH, 2012

Research Interests

Dr. Wenzler's research is centered around the pharmacokinetics and pharmacodynamics of antimicrobials in both the in vitro and clinical arenas as well as outcomes based research related to infectious diseases. His laboratory research focuses on discovering optimal antimicrobial treatment regimens against multidrug resistant bacteria, including evaluating synergistic antimicrobial combinations targeted at emerging super resistant Gram negative pathogens such as those harboring metallo-beta-lactamase and class D serine beta-lactamase enzymes. He is also interested in the activity of antimicrobials in the genitourinary tract and optimizing the use of inhaled antibiotics for the treatment of pneumonia. His primary clinical research emphasis is investigating antimicrobial pharmacokinetics after novel dosing regimens in healthy volunteers and in special patient populations including critically ill patients and those receiving forms of hemodialysis. His outcomes research attempts to translate and apply the in vitro and clinical research findings to patients afflicted with infectious diseases syndromes, specifically exploring the impact of bacterial genotypic-phenotypic relationships on the clinical outcomes of patients infected with resistant pathogens.

Professional Organizations

  • Vice-Chair, Infectious Diseases Practice Research Network, American College of Clinical Pharmacy
  • Internet and Social Media Committee, Society of Infectious Diseases Pharmacists
  • Editor-in-Chief, Journal of Antimicrobial Stewardship
  • Section of Clinical Specialists and Scientists' Executive Committee Section Advisory Group on Emerging Sciences, American Society of Health-System Pharmacists
  • American Society of Microbiology
  • Making a Difference in Infectious Diseases Pharmacotherapy
  • Ohio Society of Health-System Pharmacists

Licenses and Certifications

  • The State of Illinois Department of Financial & Professional Regulation, Illinois Pharmacist Licensure, 2014
  • The State of Ohio Board of Pharmacy, Ohio Pharmacist Licensure, 2012
  • American Heart Association, Advanced Cardiovascular Life Support Certified, 2011
  • American Academy of HIV Medicine, American Academy of HIV Medicine HIV Pharmacist Credential (AAHIVP), 2017
  • Board of Pharmacy Specialists, Board Certified Pharmacotherapy Specialist (BCPS), 2013

Intellectual Contributions

Manuscript

  • Bunnell KL, Pai MP, Sikka M, Beasdale SC, Wenzler E, Danziger LH, Rodvold KA. "Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.". Antimicrob Agents Chemother. 2018;62(4):e02475-17. doi:10.1128/AAC.02475-17.

Journal Article

  • Wenzler E, Bunnell KL, Danziger LH. "Clinical use of the polymyxins: the tale of the fox and the cat.". International journal of antimicrobial agents. 2018;51(5):700-706. doi:10.1016/j.ijantimicag.2017.12.023.
  • Bunnell KL, Wenzler E, Harrington AT, Danziger LH. "Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.". Diagnostic microbiology and infectious disease. 2018;90(4):335-336. doi:10.1016/j.diagmicrobio.2017.12.007.
  • Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. "Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.". Antimicrobial agents and chemotherapy. 2018;62(4). doi:10.1128/AAC.02475-17.
  • Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger LH, Wenzler E. "Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile.". Annals of clinical microbiology and antimicrobials. 2017;16(1):77. doi:10.1186/s12941-017-0252-7.
  • Bauer KA, Johnston JEW , Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, Pancholi P, Mangino JE. "Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.". Anaerobe. 2017;48:1-6. doi:10.1016/j.anaerobe.2017.06.009.
  • Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA. "Reply to Dilworth et al.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;65(11):1957-1958. doi:10.1093/cid/cix677.
  • Wenzler E, Ellis-Grosse EJ, Rodvold KA. "Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.". Antimicrobial agents and chemotherapy. 2017;61(9). doi:10.1128/AAC.00775-17.
  • Wenzler E, Deraedt MF, Harrington AT, Danizger LH. "Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.". Diagnostic microbiology and infectious disease. 2017;88(4):352-354. doi:10.1016/j.diagmicrobio.2017.05.009.
  • Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA. "An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;65(2):194-200. doi:10.1093/cid/cix315.
  • Wenzler E, Bunnell KL, Bleasdale SC, Benken ST, Danziger LH, Rodvold KA. "Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.". Antimicrobial agents and chemotherapy. 2017;61(7). doi:10.1128/AAC.00464-17.
  • Wenzler E, Goff DA, Humphries R, Goldstein EJC . "Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.". Infectious diseases and therapy. 2017;6(2):149-172. doi:10.1007/s40121-017-0149-y.
  • Meyer K, Santarossa M, Danziger LH, Wenzler E. "Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.". Hospital pharmacy. 2017;52(3):221-228. doi:10.1310/hpj5203-221.
  • Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. "Inhaled Antibiotics for Gram-Negative Respiratory Infections.". Clinical microbiology reviews. 2016;29(3):581-632. doi:10.1128/CMR.00101-15.
  • Wenzler E, Wong JR, Goff DA, Jankowski CA, Bauer KA. "Controversies in Antimicrobial Stewardship: Focus on New Rapid Diagnostic Technologies and Antimicrobials.". Antibiotics (Basel, Switzerland). 2016;5(1). doi:10.3390/antibiotics5010006.
  • Wenzler E, Goff DA, Mangino JE, Reed EE, Wehr A, Bauer KA. "Impact of rapid identification of Acinetobacter Baumannii via matrix-assisted laser desorption ionization time-of-flight mass spectrometry combined with antimicrobial stewardship in patients with pneumonia and/or bacteremia.". Diagnostic microbiology and infectious disease. 2016;84(1):63-68. doi:10.1016/j.diagmicrobio.2015.09.018.
  • Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA. "Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.". Antimicrobial agents and chemotherapy. 2015;59(12):7232-9. doi:10.1128/AAC.01713-15.
  • Wenzler E, Chandrasekaran V, Salvador P, Anwar M, Pancholi P, McGwire BS. "Clinical and microbiological outcomes in patients with Streptococcus anginosus group bacteraemia identified through use of a rapid microarray assay.". Journal of medical microbiology. 2015;64(11):1369-74. doi:10.1099/jmm.0.000176.
  • Wenzler E, Rodvold KA. "Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;61 Suppl 2:S38-47. doi:10.1093/cid/civ522.
  • Wenzler E, Mulugeta SG, Danziger LH. "The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.". Antibiotics (Basel, Switzerland). 2015;4(2):198-215. doi:10.3390/antibiotics4020198.
  • Wenzler E, Kamboj K, Balada-Llasat JM. "Severe Sepsis Secondary to Persistent Lysinibacillus sphaericus, Lysinibacillus fusiformis and Paenibacillus amylolyticus Bacteremia.". International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2015;35:93-5. doi:10.1016/j.ijid.2015.04.016.

Other

  • Wenzler E, Danziger LH. (2016). "Urinary Tract Infections: Resistance Is Futile.". Antimicrobial agents and chemotherapy. Vol. 60. Issue 4. Page(s) 2596-7.
  • Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH. (2015). "Hepatitis C Management and the Infectious Diseases Pharmacist.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 61. Issue 7. Page(s) 1201-2.
  • Wenzler E, Rodvold KA, Danziger LH. (2015). "Editorial commentary: improving prescribers to advance antimicrobial stewardship.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 60. Issue 8. Page(s) 1259-61.
Top